US Stock Market Move | Weight loss drug sector stocks fall, Eli Lilly (LLY.US) plummets over 5%

On Thursday, the weight loss drug sector came under pressure. As of the time of writing, Eli Lilly (LLY.US) plummeted over 5%, with the company's weight loss drugs being added to the FDA review list, delaying the decision until April 10, 2026. Novo Nordisk A/S Sponsored ADR Class B (NVO.US) fell over 4%, while Pfizer Inc. (PFE.US) and Amgen (AMGN.US) dropped over 1%.